Diffuse Midline Glioma, H3 K27M-Mutant — Trials

Diffuse Midline Glioma, H3 K27M-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 29%
Top sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06161974	Study of Olutasidenib and Temozolomide in HGG	recruiting	Phase 2	60	Rigel PharmaceuticalsINDUSTRY	7	Sep 1, 2026	clinicaltrials
NCT05009992	Combination Therapy for the Treatment of Diffuse Midline Gliomas(PNOC022)	recruiting	Phase 2	360	University of California, San FranciscoOTHER	6	Jun 26, 2026	clinicaltrials